For research use only. Not for therapeutic Use.
BGP-15 is a nicotinamide oxime derivative with PARP inhibitory activity. BGP-15 has been found to play a protective role after ischemia-reperfusion injury. BGP-15 inhibits cisplatin-induced adenosine diphosphate ribose polymerization in the kidney. At the same time, BGP-15 can restore cisplatin-induced energy metabolism disorders and maintain ATP levels in its protective tissues.
Catalog Number | I004506 |
CAS Number | 66611-37-8 |
Synonyms | N-[2-hydroxy-3-(1-piperidinyl)propoxy]-3-pyridinecarboximidamide, dihydrochloride |
Molecular Formula | C14H22N4O2 • 2HCl |
Purity | ≥95% |
Target | Epigenetics |
Solubility | DMSO: ≤ 11.33 mg/mL |
Storage | -20°C |
IUPAC Name | N'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride |
InChI | InChI=1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H |
InChIKey | ISGGVCWFTPTHIX-UHFFFAOYSA-N |
SMILES | C1CCN(CC1)CC(CON=C(C2=CN=CC=C2)N)O.Cl.Cl |
Reference | <p> |